A new study led by Henry Ford Health System reveals that hydroxychloroquine cut the death rate significantly in patients hospitalized with COVID-19—and without heart-related side effects. The large-scale retrospective analysis of 2,541 patients was recently published in the International Journal of Infectious Diseases.
This study does counter to a number of claims and trends of late where hydroxychloroquine fell out of favor, perhaps as TrialSite News has reported, due to various mishaps and perhaps some politics.
This retrospective study involved the analysis of patients hospitalized from March 10 to May 2, 2020 across the system’s six hospitals. The investigators found that 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine. None of the patients, reports the Henry Ford Health System, experienced serious heart abnormalities. However, patients were monitored for a heart condition routinely pointed to as a reason to avoid the drug as a COVID-19 treatment.
Patients treated with hydroxychloroquine at Henry Ford met specific protocol criteria as outlined by the hospital system’s Division ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).